Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections

Basilea Pharmaceutica

Status

Conditions: Invasive Fungal Infections

Treatments: Drug: Fosmanogepix solution for infusion; Drug: Fosmanogepix 400 mg tablets

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT06433128

EAP to Fosmanogepix

Details and patient eligibility

About

The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.